Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesPreferred Shares IssuedShare-based CompensationShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Bioadaptives (BDPT) Share-based Compensation (2019 - 2025)

Bioadaptives' Share-based Compensation history spans 5 years, with the latest figure at $105000.0 for Q4 2025.

  • Quarterly results put Share-based Compensation at $105000.0 for Q4 2025, down 49.73% from a year ago — trailing twelve months through Dec 2025 was $443670.0 (up 112.41% YoY), and the annual figure for FY2025 was $443670.0, up 112.41%.
  • Share-based Compensation for Q4 2025 was $105000.0 at Bioadaptives, roughly flat from $105000.0 in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $208871.0 in Q4 2024 to a low of $90000.0 in Q1 2025.
  • The 3-year median for Share-based Compensation is $124335.0 (2025), against an average of $136073.5.
  • The sharpest move saw Share-based Compensation skyrocketed 1496.84% in 2021, then tumbled 49.73% in 2025.
  • Year by year, Share-based Compensation stood at $163900.0 in 2021, then grew by 27.44% to $208871.0 in 2024, then tumbled by 49.73% to $105000.0 in 2025.
  • According to Business Quant data, Share-based Compensation over the past three periods came in at $105000.0, $105000.0, and $143670.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.